Category: Investment, Biotech, Pharma
Stem Cell Stock Alert: BioRestorative (OTCBB: BRTX) Engages Consulting Firm to Advance brtxDISCâ„¢ Program Delivery Device through FDA Clearance Process
JUPITER, Fla. - September 30, 2013 (Investorideas.com Newswire) BioRestorative Therapies Inc. ("BRT" or the "Company") (OTCQB: BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC ("PTA") to help advance the Company's brtxDISCâ„¢ therapeutic procedure through the U.S. Food and Drug Administration ("FDA") regulatory process. The brtxDISCâ„¢ program is the Company's non-surgical investigative treatment for bulging and herniated lumbar discs.
Under the engagement, PTA will assist the Company in its efforts to obtain U.S. regulatory approval and to satisfy FDA regulations applicable to the Company's medical device used in the brtxDISCâ„¢ procedure, including the implementation of quality systems procedures. In addition, PTA will assist BRT in its efforts to satisfy FDA regulations relevant to the combination products (biologic plus device) it ultimately plans to commercialize in the U.S. PTA is also available to assist in any international regulatory approval processes the Company may pursue.
"This is an important step in advancing the development of our brtxDISCâ„¢ procedure," said Mark Weinreb, chief executive officer of BioRestorative Therapies. "We have developed a minimally invasive, technologically innovative medical device to precisely deliver a patient's own stem cells directly into the damaged region of the herniated and bulging disc, which is a key component of the success of the procedure."
"There are approximately one million aggressive surgical back and spine procedures in the U.S. each year, including discectomies, disc replacements and spinal fusions. Our goal is to offer an alternative to these procedures by providing a cellular procedure to assist the patient's body in repairing the disc. Pending regulatory approval, we look forward to commencing clinical trials in mid-2014," Mr. Weinreb added.
Phil Triolo and Associates, LC provides services to assure compliance with U.S. regulatory requirements during all stages of the product lifecycle, from feasibility, design and development, to manufacturing, post-production vigilance and audits.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
- brtxDISCâ„¢ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
- ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Contact:
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative has compensated Investoridea for a six month news program ( five thousand ) to be published on Investorideas.com newswire and syndication and social media partners.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894